Last reviewed · How we verify
Amonafide L-Malate
Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells.
Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells. Used for Acute myeloid leukemia.
At a glance
| Generic name | Amonafide L-Malate |
|---|---|
| Sponsor | Xanthus Pharmaceuticals, Inc. |
| Drug class | Topoisomerase II inhibitor |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Amonafide L-Malate works by binding to the DNA minor groove, which prevents the progression of DNA replication and transcription. This leads to the induction of apoptosis in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of topoisomerase II and the induction of DNA damage.
Approved indications
- Acute myeloid leukemia
Common side effects
- Myelosuppression
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) (PHASE2)
- Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study (PHASE3)
- Study of Individualized Amonafide to Treat Prostate Cancer (PHASE1, PHASE2)
- Amonafide in Combination With Cytarabine in Secondary AML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amonafide L-Malate CI brief — competitive landscape report
- Amonafide L-Malate updates RSS · CI watch RSS
- Xanthus Pharmaceuticals, Inc. portfolio CI